-
Mashup Score: 2Alpha-9 Oncology doses first subject in phase 1 study for new melanoma diagnostic agent - 13 day(s) ago
The first participant has been dosed in the phase 1 study evaluating Ga-A9-3202 for locally advanced or metastatic melanoma imaging, Alpha-9 Oncology announced in a press release.Ga-A9-3202 is a radiodiagnostic that targets the melanocortin 1 receptor (MC1R). The expression of this receptor is known to be elevated in malignant melanoma and other types of skin cancers, positioning Ga-A9-3202 as a
Source: www.healio.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US - BMC Cancer - 2 month(s) ago
Background The objective of this study was to describe real-world adjuvant therapy (AT) use by disease substage and assess determinants of treatment choice among patients with stage III melanoma. Methods This non-interventional retrospective study included survey responses and data from patient records provided by US medical oncologists. Survey responses, patient demographic/clinical characteristics, treatment utilization, and reasons for treatment were reported descriptively. The association between patient and disease characteristics and AT selection was assessed using logistic and multinomial regression models, overall and stratified by AJCC8 substage (IIIA vs. IIIB/C/D) and type of AT received (anti-PD1 monotherapy, BRAF/MEK, no AT), respectively. Results In total 152 medical oncologists completed the survey and reviewed the charts of 507 patients (168 stage IIIA; 339 stages IIIB/IIIC/IIID); 405 (79.9%) patients received AT (360/405 (88.9%) received anti-PD1 therapy; 45/405 (11.1%)
Source: link.springer.comCategories: General Medicine News, Hem/OncsTweet-
Important study on real-world use of and decision making about #adjuvanttherapy for #melanoma across the USA https://t.co/OpofYsIMhD via @SpringerNature with support from @Merck
-
-
Mashup Score: 06 Cancer Screenings to Schedule this Year | Atlantic Health - 2 month(s) ago
Cancer screenings can catch the disease before you have symptoms and when it’s most treatable. Learn which screenings might be right for you.
Source: www.atlantichealth.orgCategories: General Medicine News, Hem/OncsTweet-
Always important to screen for early cancer detection, when virtually all cancers are at their most curable. Nice and timely article to be quoted in: https://t.co/6pQ26Zfe2B
-
-
Mashup Score: 1Atlantic Health System is Seeking Oncologists for Multiple Opportunities in NJ - Opportunities in Morristown, Summit, and Bridgewater New Jersey - 4 month(s) ago
Atlantic Health System (AHS) is actively recruiting passionate and skilled oncologists for multiple opportunities across Atlantic Health System. AH…
Source: careercenter.asco.orgCategories: General Medicine News, Hem/OncsTweet-
As our #cancer program expands, we need more physicians to help our patients! Great opportunties available here: https://t.co/zK6GNu5Bkc
-
-
Mashup Score: 2Virginia high school student creates soap to fight skin cancer, is awarded $25K: 'Remarkable effort' - 7 month(s) ago
A Virginia high school freshman created a soap to treat skin cancer. Heman Bekele was awarded $25,000 after winning this year’s 3M Young Scientist Challenge — Fox News Digital spoke to his mom.
Source: www.foxnews.comCategories: General Medicine News, Hem/OncsTweet-
Thanks to @FoxNews for quoting my response to #skincancer soap developed by a young researcher. Next stop on @thefive? @Gutfeldfox? @SpecialReport? doubtful... https://t.co/G6qpepHNQa
-
-
Mashup Score: 0Sirnaomics Announces Successful Phase I Clinical Study of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors - 9 month(s) ago
Sirnaomics Ltd. (the “Company”, Stock Code: 2257.HK, together with its subsidiaries, the “Group” or “Sirnaomics”), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced the Group has completed all dosing regimens for its Phase I study of STP707 for the treatment of multiple solid tumors in patients with various types of late-stage cancers who did not respond to multiple rounds of other oncology treatments. Approximately 74% of evaluable patients d
Source: finance.yahoo.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Excited to see these results released and happy we were part of this study through our PI @DrAngelaAlistar We (@AtlanticHealth ) eagerly await next steps with this agent. https://t.co/vxsW77eAtD
-
-
Mashup Score: 0Atlantic Health System Cancer Care enrolls first patient in eastern US in groundbreaking non-Hodgkin lymphoma drug trial - 11 month(s) ago
Atlantic Health System Cancer Care is the only site on the east coast to enroll a patient in a new trial of a groundbreaking medication for non-Hodgkin lymphoma
Source: www.newswise.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Congrats to @DrMCherry for enrolling and treating the first patient at our center (and east of Ohio) on this exciting trial of allogeneic CAR-T cells for #lymphoma sponsored by @CaribouBio https://t.co/q12JZdlhgS @AtlanticHealth
-
-
Mashup Score: 0Newsweek's 175 top cancer hospitals in the US, ranked by state - 11 month(s) ago
Newsweek has released its annual list of America’s Best Cancer Hospitals for 2023.
Source: www.beckershospitalreview.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Excited to share that our flagship hospital, Morristown Medical Center of @AtlanticHealth, is included in the @Newsweek 2023 Best Cancer Hospitals listing, ranked above many prominent, well-known universities and other accomplished centers: https://t.co/KwCojT8lYz
-
-
Mashup Score: 0Newsweek's 175 top cancer hospitals in the US, ranked by state - 11 month(s) ago
Newsweek has released its annual list of America’s Best Cancer Hospitals for 2023.
Source: www.beckershospitalreview.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Excited to share that our flagship hospital, Morristown Medical Center of @AtlanticHealth, is included in the @Newsweek 2023 Best Cancer Hospitals listing, ranked about many prominent, well-known universities and other accomplished centers: https://t.co/KwCojT8lYz
-
-
Mashup Score: 0
The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerabilityPositive clinical responses were reported…
Source: GlobeNewswire News RoomCategories: Hem/Oncs, Latest HeadlinesTweet-
AI-powered study to look at tumor #antigen target optimization in #melanoma and potentially other cancers. Always have to be careful when touting "immunologic responses" as these may not necessarily lead to actual clinical effects ie tumor shrinkage https://t.co/Up3OH7cuW6
-
Something to keep an eye, a #melanoma tumor specific imaging agent, to hopefully improve our ability to detect residual or recurrent disease: https://t.co/5XDtfCyBUO